Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Vaccines

Free Subscription Articles published in Lancet Retrieve available abstracts of 74 articles: HTML format Text format

Single Articles

May 2018
1. WINSTON DJ, Mullane KM, Cornely OA, Boeckh MJ, et al
   Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
   Lancet. 2018;391:2116-2127.
   PubMed     Text format     Abstract available
   
   
   
2. CORCORAN B, Clarke A, Barrett T
   Rapid response to HPV vaccination crisis in Ireland.
   Lancet. 2018;391:2103.
   PubMed     Text format    
   
   
   
3. MACARTNEY K, Gershon AA
   Shingles vaccine after auto-HSCT decreases risk.
   Lancet. 2018;391:2082-2084.
   PubMed     Text format    
   
   
   
4. KELLY JD, Mukadi P, Dhillon RS
   Beyond vaccines: improving survival rates in the DRC Ebola outbreak.
   Lancet. 2018 May 25. pii: S0140-6736(18)31212.
   PubMed     Text format    
   
   
   
5. QADRI F, Azad AK, Flora MS, Khan AI, et al
   Emergency deployment of oral cholera vaccine for the Rohingya in Bangladesh.
   Lancet. 2018;391:1877-1879.
   PubMed     Text format    
   
   
   
6. AGUIAR M
   Dengue vaccination: a more ethical approach is needed.
   Lancet. 2018;391:1769-1770.
   PubMed     Text format    
   
   
   
7. HARGREAVES S, Nellums LB, Ramsay M, Saliba V, et al
   Who is responsible for the vaccination of migrants in Europe?
   Lancet. 2018;391:1752-1754.
   PubMed     Text format    
   
   
   April 2018
8. THE LANCET
   Addressing decreasing vaccine coverage in the EU.
   Lancet. 2018;391:1638.
   PubMed     Text format    
   
   
   March 2018
9. PENG X, Hu X, Salazar MA
   On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine.
   Lancet. 2018 Mar 28. pii: S0140-6736(18)30483.
   PubMed     Text format    
   
   
   
10. WATTS G
    New York Challenge sets high bar for HPV vaccination.
    Lancet. 2018;391:1137.
    PubMed     Text format    
    
    
    
11. METZGER WG, Vivas-Martinez S
    Questionable efficacy of the rVSV-ZEBOV Ebola vaccine.
    Lancet. 2018;391:1021.
    PubMed     Text format    
    
    
    
12. LONGINI IM, Rottingen JA, Kieny MP, Edmunds WJ, et al
    Questionable efficacy of the rVSV-ZEBOV Ebola vaccine - Authors' reply.
    Lancet. 2018;391:1021-1022.
    PubMed     Text format    
    
    
    February 2018
13. PANG T, Gubler D, Goh DYT, Ismail Z, et al
    Dengue vaccination: a more balanced approach is needed.
    Lancet. 2018;391:654.
    PubMed     Text format    
    
    
    
14. LARSON HJ
    A global girl gang.
    Lancet. 2018;391:527-528.
    PubMed     Text format    
    
    
    
15. PAULES CI, Subbarao K
    Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.
    Lancet. 2018;391:427-428.
    PubMed     Text format    
    
    
    
16. CALDEIRA D, Ferreira JJ, Costa J
    Influenza vaccination and prevention of cardiovascular disease mortality.
    Lancet. 2018;391:426-427.
    PubMed     Text format    
    
    
    
17. THE LANCET
    Yellow fever: a major threat to public health.
    Lancet. 2018;391:402.
    PubMed     Text format    
    
    
    January 2018
18. THE LANCET
    A new vaccine for typhoid control.
    Lancet. 2018;391:96.
    PubMed     Text format    
    
    
    
19. PETOUSIS-HARRIS H, Paynter J, Morgan J, Saxton P, et al
    Pitfalls of the healthy vaccinee effect - Authors' reply.
    Lancet. 2018;391:123-124.
    PubMed     Text format    
    
    
    
20. MAHMUD SM, Righolt CH
    Pitfalls of the healthy vaccinee effect.
    Lancet. 2018;391:123.
    PubMed     Text format    
    
    
    
21. ZAFFRAN M, McGovern M, Hossaini R, Martin R, et al
    The polio endgame: securing a world free of all polioviruses.
    Lancet. 2018;391:11-13.
    PubMed     Text format    
    
    
    December 2017
22. MASTERSON L, O'Mahony J, Lechner M
    Expanding the benefits of HPV vaccination to boys and men.
    Lancet. 2017;388:2992.
    PubMed     Text format    
    
    
    
23. MARQUES ETA, Burke DS
    Tradition and innovation in development of a Zika vaccine.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33107.
    PubMed     Text format    
    
    
    
24. GAUDINSKI MR, Houser KV, Morabito KM, Hu Z, et al
    Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33105.
    PubMed     Text format     Abstract available
    
    
    
25. MODJARRAD K, Lin L, George SL, Stephenson KE, et al
    Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33106.
    PubMed     Text format     Abstract available
    
    
    October 2017
26. YIN Y
    HPV vaccination in China needs to be more cost-effective.
    Lancet. 2017;390:1735-1736.
    PubMed     Text format    
    
    
    September 2017
27. JIN C, Gibani MM, Moore M, Juel HB, et al
    Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
    Lancet. 2017 Sep 28. pii: S0140-6736(17)32149.
    PubMed     Text format     Abstract available
    
    
    
28. FEASEY NA, Levine MM
    Typhoid vaccine development with a human challenge model.
    Lancet. 2017 Sep 28. pii: S0140-6736(17)32407.
    PubMed     Text format    
    
    
    
29. HUH WK, Joura EA, Giuliano AR, Iversen OE, et al
    Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
    Lancet. 2017 Sep 5. pii: S0140-6736(17)31821.
    PubMed     Text format     Abstract available
    
    
    
30. DENNY L
    Nine-valent human papillomavirus vaccine: great science, but will it save lives?
    Lancet. 2017 Sep 5. pii: S0140-6736(17)32144.
    PubMed     Text format    
    
    
    July 2017
31. HINMAN AR, Orenstein WA
    Collaborating to achieve Global Vaccine Action Plan goals.
    Lancet. 2017;390:451-452.
    PubMed     Text format    
    
    
    
32. ALBERER M, Gnad-Vogt U, Hong HS, Mehr KT, et al
    Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.
    Lancet. 2017 Jul 25. pii: S0140-6736(17)31665.
    PubMed     Text format     Abstract available
    
    
    
33. WARRELL M
    Is there a future for mRNAs as viral vaccines?
    Lancet. 2017 Jul 25. pii: S0140-6736(17)31964.
    PubMed     Text format    
    
    
    
34. PETOUSIS-HARRIS H, Paynter J, Morgan J, Saxton P, et al
    Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study.
    Lancet. 2017 Jul 7. pii: S0140-6736(17)31449.
    PubMed     Text format     Abstract available
    
    
    
35. SEIB KL
    Gonorrhoea vaccines: a step in the right direction.
    Lancet. 2017 Jul 7. pii: S0140-6736(17)31605.
    PubMed     Text format    
    
    
    June 2017
36. ROUPHAEL NG, Paine M, Mosley R, Henry S, et al
    The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.
    Lancet. 2017 Jun 27. pii: S0140-6736(17)30575.
    PubMed     Text format     Abstract available
    
    
    
37. HOSCHLER K, Zambon MC
    Influenza vaccine: going through a sticky patch.
    Lancet. 2017 Jun 27. pii: S0140-6736(17)31364.
    PubMed     Text format    
    
    
    
38. ZAROCOSTAS J
    Cholera outbreak in Haiti-from 2010 to today.
    Lancet. 2017;389:2274-2275.
    PubMed     Text format    
    
    
    March 2017
39. THE LANCET
    Evaluating industry's role in vaccine access.
    Lancet. 2017;389:984.
    PubMed     Text format    
    
    
    February 2017
40. CHAN M, Elias C, Fauci A, Lake A, et al
    Reaching everyone, everywhere with life-saving vaccines.
    Lancet. 2017;389:777-779.
    PubMed     Text format    
    
    
    January 2017
41. CLINTON C, Sridhar D
    Who pays for cooperation in global health? A comparative analysis of WHO, the World Bank, the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria, and Gavi, the Vaccine Alliance.
    Lancet. 2017 Jan 27. pii: S0140-6736(16)32402.
    PubMed     Text format     Abstract available
    
    
    December 2016
42. HENAO-RESTREPO AM, Camacho A, Longini IM, Watson CH, et al
    Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!).
    Lancet. 2016 Dec 23. pii: S0140-6736(16)32621.
    PubMed     Text format     Abstract available
    
    
    
43. GROBUSCH MP, Goorhuis A
    Safety and immunogenicity of a recombinant adenovirus vector-based Ebola vaccine.
    Lancet. 2016 Dec 22. pii: S0140-6736(16)32619.
    PubMed     Text format    
    
    
    
44. GEISBERT TW
    First Ebola virus vaccine to protect human beings?
    Lancet. 2016 Dec 22. pii: S0140-6736(16)32618.
    PubMed     Text format    
    
    
    
45. ZHU FC, Wurie AH, Hou LH, Liang Q, et al
    Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2016 Dec 22. pii: S0140-6736(16)32617.
    PubMed     Text format     Abstract available
    
    
    
46. PARIKH SR, Andrews NJ, Beebeejaun K, Campbell H, et al
    Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.
    Lancet. 2016;388:2775-2782.
    PubMed     Text format     Abstract available
    
    
    
47. BASTA NE, Christensen H
    4CMenB vaccine effectiveness: reasons for optimism.
    Lancet. 2016;388:2719-2721.
    PubMed     Text format    
    
    
    November 2016
48. ASTURIAS EJ, Bandyopadhyay AS, Clemens R, Orenstein W, et al
    New poliovirus vaccine schedules - Authors' reply.
    Lancet. 2016;388:2478.
    PubMed     Text format    
    
    
    
49. ZHANG Q, Leppold C, Shao Y, Mura Y, et al
    New poliovirus vaccine schedules.
    Lancet. 2016;388:2477-2478.
    PubMed     Text format    
    
    
    
50. THE LANCET
    Measles vaccination: global progress, local challenges.
    Lancet. 2016;388:2450.
    PubMed     Text format    
    
    
    
51. WU JT, Peak CM, Leung GM, Lipsitch M, et al
    Fractional dosing of yellow fever vaccine to extend supply: a modelling study.
    Lancet. 2016 Nov 9. pii: S0140-6736(16)31838.
    PubMed     Text format     Abstract available
    
    
    
52. DENNY L, de Sanjose S, Mutebi M, Anderson BO, et al
    Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries.
    Lancet. 2016 Nov 1. pii: S0140-6736(16)31795.
    PubMed     Text format     Abstract available
    
    
    October 2016
53. HALSTEAD SB, Aguiar M
    Is discussion of dengue vaccination for the 2016 Olympics necessary?: Authors' reply.
    Lancet. 2016;388:1881-1882.
    PubMed     Text format    
    
    
    
54. SCHWARZ TF
    Is discussion of dengue vaccination for the 2016 Olympics necessary?
    Lancet. 2016;388:1881.
    PubMed     Text format    
    
    
    
55. ARREDONDO-GARCIA JL, Hadinegoro SR, Guy B, Bouckenooghe A, et al
    Is discussion of dengue vaccination for the 2016 Olympics necessary?
    Lancet. 2016;388:1880-1881.
    PubMed     Text format    
    
    
    
56. WANG LD, Lam WW, Fielding R
    Parental decision-making with regards to vaccination against human papilloma virus in adolescent girls in Hong Kong, China: a prospective cohort study.
    Lancet. 2016;388 Suppl 1:S78.
    PubMed     Text format     Abstract available
    
    
    September 2016
57. AKANMORI BD, Mukanga DO, Mihigo R, Ward M, et al
    New development of medicines for priority diseases in Africa.
    Lancet. 2016;388:1053-4.
    PubMed     Text format    
    
    
    
58. ELACHOLA H, Ditekemena J, Zhuo J, Gozzer E, et al
    Yellow fever outbreaks, vaccine shortages and the Hajj and Olympics: call for global vigilance.
    Lancet. 2016 Sep 5. pii: S0140-6736(16)31546.
    PubMed     Text format    
    
    
    August 2016
59. DOIRON PR, Bunker CB
    Expanding the benefits of HPV vaccination to boys and men.
    Lancet. 2016;388:659.
    PubMed     Text format    
    
    
    July 2016
60. THE LANCET
    HPV vaccination: a decade on.
    Lancet. 2016;388:438.
    PubMed     Text format    
    
    
    
61. MAURICE J
    The Zika virus public health emergency: 6 months on.
    Lancet. 2016;388:449-50.
    PubMed     Text format    
    
    
    
62. HALSTEAD SB, Aguiar M
    Dengue vaccine and the 2016 Olympics.
    Lancet. 2016;388:237-8.
    PubMed     Text format    
    
    
    June 2016
63. GREEN A
    Yellow fever continues to spread in Angola.
    Lancet. 2016;387:2493.
    PubMed     Text format    
    
    
    
64. MAYER KH, Shisana O, Beyrer C
    AIDS 2016: from aspiration to implementation.
    Lancet. 2016;387:2484-5.
    PubMed     Text format    
    
    
    
65. QIU J, Hu H, Zhou S, Liu Q, et al
    Vaccine scandal and crisis in public confidence in China.
    Lancet. 2016;387:2382.
    PubMed     Text format    
    
    
    
66. MCGILL F, Heyderman RS, Panagiotou S, Tunkel AR, et al
    Acute bacterial meningitis in adults.
    Lancet. 2016 Jun 2. pii: S0140-6736(16)30654.
    PubMed     Text format     Abstract available
    
    
    May 2016
67. CHAN M
    Yellow fever: the resurgence of a forgotten disease.
    Lancet. 2016;387:2165-6.
    PubMed     Text format    
    
    
    
68. ASTURIAS EJ, Bandyopadhyay AS, Self S, Rivera L, et al
    Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
    Lancet. 2016 May 19. pii: S0140-6736(16)00703.
    PubMed     Text format     Abstract available
    
    
    
69. PARKER EP, Grassly NC
    Polio vaccination: preparing for a change of routine.
    Lancet. 2016 May 19. pii: S0140-6736(16)30593.
    PubMed     Text format    
    
    
    
70. O'BRIEN KL, Binka F, Marsh K, Abramson JS, et al
    Mind the gap: jumping from vaccine licensure to routine use.
    Lancet. 2016;387:1887-9.
    PubMed     Text format    
    
    
    April 2016
71. SCHMELER KM, Sturgis EM
    Expanding the benefits of HPV vaccination to boys and men.
    Lancet. 2016;387:1798-9.
    PubMed     Text format    
    
    
    
72. LOCARNINI S, Chen DS, Shibuya K
    No more excuses: viral hepatitis can be eliminated.
    Lancet. 2016;387:1703-4.
    PubMed     Text format    
    
    
    
73. 
    Yellow fever: a global reckoning.
    Lancet. 2016;387:1348.
    PubMed     Text format    
    
    
    February 2016
74. WILLISON HJ, Jacobs BC, van Doorn PA
    Guillain-Barre syndrome.
    Lancet. 2016 Feb 29. pii: S0140-6736(16)00339.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: